Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A new site revision entry (v3.6.3) was added to the page history, replacing the previous revision (v3.6.0) and indicating an update to the ClinicalTrials.gov interface.
    Difference
    0.0%
    Check dated 2026-06-30T01:08:47.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    A new revision entry (v3.6.0) was added with a note that the study is no longer looking for participants. The previous revision (v3.5.5) was removed.
    Difference
    0.2%
    Check dated 2026-06-15T18:46:45.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Footer revision updated from v3.5.4 to v3.5.5, representing a new build of the ClinicalTrials.gov interface.
    Difference
    0.0%
    Check dated 2026-06-08T16:31:37.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    A new site revision is recorded as v3.5.4, superseding the previous v3.5.3. This reflects an update to the page's version metadata in the history.
    Difference
    0.1%
    Check dated 2026-05-18T03:46:02.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    The page footer revision label was updated from v3.5.2 to v3.5.3, reflecting a new site build rather than any alteration to the study record information.
    Difference
    0.0%
    Check dated 2026-04-26T15:16:51.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    The page history now includes Revision: v3.5.2, and Revision: v3.5.0 has been removed.
    Difference
    0.0%
    Check dated 2026-04-19T12:44:34.000Z thumbnail image

Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.